Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C

Altunok, Elif; SAYAN, MURAT; AKHAN, SILA; AYGEN, BİLGEHAN; YILDIZ, ORHAN; Koruk, Suda; Mistik, Resit; Demirturk, Nese; Ural, Onur; Kose, Sukran; Aynioglu, Aynur; Korkmaz, Fatime; Ersoz, Gulden; Tuna, Nazan; Ayaz, Celal; Karakecili, Faruk; Keten, Derya; Inan, Dilara; Yazici, Saadet; Koculu, Safiye; Yildirmak, Taner

doi:10.1016/j.ijid.2016.07.003

Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C

Atıf İçin Kopyala

Altunok E. S., SAYAN M., AKHAN S., AYGEN B., YILDIZ O., Koruk S. T., ...Daha Fazla

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, cilt.50, ss.1-5, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 50
Basım Tarihi: 2016
Doi Numarası: 10.1016/j.ijid.2016.07.003
Dergi Adı: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1-5
Erciyes Üniversitesi Adresli: Evet

Özet

Background: Drug resistance development is an expected problem during treatment with protease inhibitors (PIs), this is largely due to the fact that Pls are low-genetic barrier drugs. Resistance-associated variants (RAVs) however may also occur naturally, and prior to treatment with Pls, the clinical impact of this basal resistance remains unknown. In Turkey, there is yet to be an investigation into the hepatitis C (HCV) drug associated resistance to oral antivirals.